Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.

Efstathios Kastritis,Angela Dispenzieri,Ashutosh D. Wechalekar,Stefan Schönland,Kihyun Kim,Vaishali Sanchorawala,Heather Landau,Fiona Kwok,Kenshi Suzuki,Raymond L. Comenzo,Giovanni Palladini,Deborah Berg,Guohui Liu,Arun Kumar,Douglas V. Faller,Giampaolo Merlini

Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.

2020

Efstathios Kastritis
Angela Dispenzieri
Ashutosh D. Wechalekar
Stefan Schönland
Kihyun Kim
Vaishali Sanchorawala
Heather Landau
Fiona Kwok
Kenshi Suzuki
Raymond L. Comenzo
Giovanni Palladini
Deborah Berg
Guohui Liu
Arun Kumar
Douglas V. Faller
Giampaolo Merlini

8546Background: The PI bortezomib is commonly used in first-line therapy of AL, but new therapies are needed that are tolerable in the context of multi-organ dysfunction and that, in RRAL, offer im...

Keywords:

Oncology
Proteasome inhibitor
Internal medicine
Ixazomib
AL amyloidosis
Pi
Pathology
Dexamethasone
Medicine
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations